MET Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MetLife Inc (MET) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the company has positive revenue growth, its declining net income, EPS, and bearish technical indicators suggest caution. Additionally, hedge fund selling and lack of strong trading signals further support a hold recommendation.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral at 48.911, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a downward trend. Key support is at 67.925, and resistance is at 70.675. The stock is currently trading near its pivot level of 69.3.
Revenue increased by 26.69% YoY in Q4 2025, showing strong top-line growth. Appointment of Jordan Canter as head of Federal Government Affairs could strengthen regulatory positioning.
Net income dropped by 37.21% YoY, and EPS fell by 34.27% YoY in Q4 2025, signaling profitability challenges. Hedge funds are aggressively selling, with a 119,940.49% increase in selling activity last quarter. Analysts have been lowering price targets, reflecting cautious sentiment.
In Q4 2025, revenue increased to $23.67 billion (+26.69% YoY), but net income dropped to $778 million (-37.21% YoY), and EPS fell to 1.17 (-34.27% YoY). This indicates strong revenue growth but significant profitability challenges.
Analyst sentiment is mixed. The most recent rating from Keefe Bruyette is Outperform with an $87 price target, but several firms have lowered their price targets recently, reflecting concerns about valuation, competition, and macro headwinds.
